Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289037 | 0.86 | TACR1 (0.60) | TACR1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL6289038 | 0.86 | TACR1 (0.60) | TACR1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL934348 | 0.83 | ALDH1A1 (0.76) | POLBALDH1A1HTTSMN1; SMN2MTNR1A | |
| SCHEMBL933858 | 0.82 | NPC1 (0.67) | KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL5670829 | 0.81 | TACR1 (0.55) | TACR1KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL2341547 | 0.81 | TACR1 (0.59) | TACR1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL5340479 | 0.80 | TACR1 (0.54) | TACR1KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL13306937 | 0.79 | TACR1 (0.52) | TACR1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL8146896 | 0.78 | MTNR1B (0.67) | ALDH1A1HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL14521466 | 0.77 | KMT2A (0.57) | TACR1KMT2AMEN1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809280-B2 | Therapeutic peptides | LYTIX BIOPHARMA AS (NO) | 2014-08-19 | — | — | US | disclosed |
| US-20130035296-A1 | THERAPEUTIC PEPTIDES | LYTIX BIOPHARMA AS (NO) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035296-A1 | THERAPEUTIC PEPTIDES | VIP, LNPEP, ANPEP | TACR1 1367/4885KMT2A 4343/4885POLB 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.